Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vβ17 peptide
- Development stage
- Unknown
- Lead developer
- Moreland
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Vβ17 peptide is a synthetic peptide derived from the variable β 17 subunit of the T cell receptor. It is designed to modulate activated T cells expressing the Vβ17 T cell receptor, which are preferentially expressed in patients with rheumatoid arthritis. The peptide works by inducing immune responses against these specific T cell populations, potentially regulating the autoimmune response involved in rheumatoid arthritis without broadly suppressing immune function.
- Other names
- T cell receptor Vβ17 peptideTCR Vβ17 peptideV beta 17 peptide
02
Targets
TRBV (T-cell receptor beta variable chain family)
Beyond the preview
Go deeper on Vβ17 peptide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vβ17 peptide.